KRAS mutations were found in 32% of the FAP samples (24% of LG adenomas and 78% of HG adenomas and carcinomas), while BRAF mutations were found in only 3% of all samples (serrated tumors were excluded from the analysis). This evidence concerns the gene KRAS and carcinoma.